Farapulse

About Farapulse

FARAPULSE operates in the medical device industry, focusing on the development and commercialization of Pulsed Field Ablation (PFA) technology for cardiac ablation procedures. The company serves healthcare providers, particularly cardiologists and electrophysiologists, who treat patients with cardiac arrhythmias. FARAPULSE's core products include a range of catheters and waveform generators designed for both endocardial (inside the heart) and epicardial (outside the heart) approaches. These products aim to create precise and durable lesions in cardiac tissue to treat arrhythmias without damaging surrounding tissues, unlike traditional thermal ablation methods such as radiofrequency and cryoablation.

The company's business model is based on the sale of its specialized catheters and waveform generators to hospitals and medical centers. Revenue is generated through the direct sale of these devices, as well as through partnerships and collaborations with other medical device companies. FARAPULSE also invests in ongoing research and development to enhance its product offerings and maintain a competitive edge in the market.

FARAPULSE operates in a highly specialized market with significant growth potential due to the increasing prevalence of cardiac arrhythmias and the demand for safer, more effective treatment options. The company's innovative approach to PFA therapy positions it as a leader in the field of cardiac ablation.